Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigam Kumar

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Peptide Science : an Official Publication of the European Peptide Society|July 15, 2010
Determination of an unusual secondary structural element in the immunostimulating tetrapeptide rigin in aqueous environments: insights via MD simulations, (1)H NMR and CD spectroscopic studiesNigam Kumar, Raghuvansh Kishore
Biopolymers|June 22, 2010
Crystallographically observed folded topology of an unsubstituted γ-aminobutyric acid incorporated in a model peptide: importance of a C--H···O interactionNigam Kumar, Paloth Venugopalan, Raghuvansh Kishore
Protein Science : a Publication of the Protein Society|January 15, 2013
Protein lysine-Nζ alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen speciesNigam Kumar, Hans Ippel, Christian Weber, et al.
Biochemistry and Biophysics Reports|September 6, 2021
Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activityRuud P M Dings, Nigam Kumar, Sterling Mikkelson, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 13, 2012
Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1Ruud P M Dings, Nigam Kumar, Michelle C Miller, et al.
Angewandte Chemie (International Ed. in English)|April 5, 2014
Reversible re-programing of cell-cell interactionsKari Gabrielse, Amit Gangar, Nigam Kumar, et al.
Journal of Medicinal Chemistry|May 12, 2012
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingRuud P M Dings, Michelle C Miller, Irina Nesmelova, et al.
Communications Biology|June 9, 2021
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacyPottayil G Sasikumar, Naremaddepalli S Sudarshan, Srinivas Adurthi, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Peptide Science : an Official Publication of the European Peptide Society|July 15, 2010
Determination of an unusual secondary structural element in the immunostimulating tetrapeptide rigin in aqueous environments: insights via MD simulations, (1)H NMR and CD spectroscopic studiesNigam Kumar, Raghuvansh Kishore
Biopolymers|June 22, 2010
Crystallographically observed folded topology of an unsubstituted γ-aminobutyric acid incorporated in a model peptide: importance of a C--H···O interactionNigam Kumar, Paloth Venugopalan, Raghuvansh Kishore
Protein Science : a Publication of the Protein Society|January 15, 2013
Protein lysine-Nζ alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen speciesNigam Kumar, Hans Ippel, Christian Weber, et al.
Biochemistry and Biophysics Reports|September 6, 2021
Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activityRuud P M Dings, Nigam Kumar, Sterling Mikkelson, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 13, 2012
Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1Ruud P M Dings, Nigam Kumar, Michelle C Miller, et al.
Angewandte Chemie (International Ed. in English)|April 5, 2014
Reversible re-programing of cell-cell interactionsKari Gabrielse, Amit Gangar, Nigam Kumar, et al.
Journal of Medicinal Chemistry|May 12, 2012
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate bindingRuud P M Dings, Michelle C Miller, Irina Nesmelova, et al.
Communications Biology|June 9, 2021
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacyPottayil G Sasikumar, Naremaddepalli S Sudarshan, Srinivas Adurthi, et al.
Pageof 1